Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SN2310 Injectable Emulsion · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | SN2310 Injectable Emulsion |
| Name | Type | Description |
|---|---|---|
| SN2310 Injectable Emulsion | DRUG | Escalating doses given IV every three weeks |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of solid tumor with disease progression despite standard therapy and/or for which no other solid therapeutic option exists * ANC \> 1,500 cell/mm3, platelets \> 100,000/mm3 and Hgb \> 9 g/dl * At least one unidimensionally me...
SN2310 Injectable Emulsion is an investigational small molecule oncology drug developed by Achieve Life Sciences, Inc. It is formulated as an injectable emulsion and was studied in patients with advanced solid tumors, including breast neoplasms. It remains in clinical development and is not an approved therapy.
SN2310 Injectable Emulsion was studied for the treatment of advanced solid tumors, with breast neoplasms among the conditions evaluated. The Phase 1 trial also enrolled patients with colorectal, pancreatic, pelvic, and lung neoplasms. Its use in breast cancer remains investigational.
SN2310 Injectable Emulsion is developed by Achieve Life Sciences, Inc., which trades under the ticker QUIT. The company sponsored the Phase 1 dose escalation study of the agent in patients with advanced solid tumors.
SN2310 Injectable Emulsion is in Phase 1 development. Its single Phase 1 dose escalation study in advanced solid tumors has been completed, and no trials of SN2310 Injectable Emulsion are currently active. The drug is investigational and has not been approved by the FDA.
SN2310 Injectable Emulsion was evaluated in one completed Phase 1 trial, NCT00385177, a dose escalation study in patients with advanced solid tumors. The study enrolled 61 participants aged 18 years and older in the United States. It was an uncontrolled, open-label study without randomization.